MX2021011301A - Terapia combinada especifica contra tumores. - Google Patents
Terapia combinada especifica contra tumores.Info
- Publication number
- MX2021011301A MX2021011301A MX2021011301A MX2021011301A MX2021011301A MX 2021011301 A MX2021011301 A MX 2021011301A MX 2021011301 A MX2021011301 A MX 2021011301A MX 2021011301 A MX2021011301 A MX 2021011301A MX 2021011301 A MX2021011301 A MX 2021011301A
- Authority
- MX
- Mexico
- Prior art keywords
- tumor
- combination therapy
- nqo1
- immunotherapy
- selective combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819870P | 2019-03-18 | 2019-03-18 | |
| PCT/US2020/023250 WO2020190990A1 (en) | 2019-03-18 | 2020-03-18 | Tumor-selective combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011301A true MX2021011301A (es) | 2022-01-19 |
Family
ID=72519160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011301A MX2021011301A (es) | 2019-03-18 | 2020-03-18 | Terapia combinada especifica contra tumores. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220160703A1 (https=) |
| EP (1) | EP3942061A4 (https=) |
| JP (1) | JP2022525476A (https=) |
| KR (1) | KR20220004025A (https=) |
| CN (1) | CN113905763A (https=) |
| AU (1) | AU2020240035A1 (https=) |
| BR (1) | BR112021018545A2 (https=) |
| CA (1) | CA3130513A1 (https=) |
| MX (1) | MX2021011301A (https=) |
| WO (1) | WO2020190990A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230128175A (ko) * | 2022-02-25 | 2023-09-04 | 주식회사 온코크로스 | 루복시스타우린을 포함하는 항암용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2619331T (pt) * | 2010-09-22 | 2018-06-01 | Univ Texas | Métodos de tratamento de cancro incluindo rastreio de nqo1 |
| CA2909091C (en) * | 2013-04-09 | 2021-11-02 | The Board Of Trustees Of The University Of Illinois | Tumor-selective combination therapy |
| WO2017025496A1 (en) * | 2015-08-12 | 2017-02-16 | Bayer Pharma Aktiengesellschaft | Pharmaceutical combination for the treatment of cancer |
| SG11201808306PA (en) * | 2016-03-24 | 2018-10-30 | Tragara Pharmaceuticals Inc | Treatment of cancer with tg02 |
| KR102922386B1 (ko) * | 2017-07-21 | 2026-02-04 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
-
2020
- 2020-03-18 KR KR1020217033464A patent/KR20220004025A/ko not_active Ceased
- 2020-03-18 BR BR112021018545A patent/BR112021018545A2/pt unknown
- 2020-03-18 MX MX2021011301A patent/MX2021011301A/es unknown
- 2020-03-18 US US17/440,787 patent/US20220160703A1/en not_active Abandoned
- 2020-03-18 JP JP2021556462A patent/JP2022525476A/ja active Pending
- 2020-03-18 CN CN202080037114.7A patent/CN113905763A/zh active Pending
- 2020-03-18 WO PCT/US2020/023250 patent/WO2020190990A1/en not_active Ceased
- 2020-03-18 EP EP20773832.9A patent/EP3942061A4/en not_active Withdrawn
- 2020-03-18 CA CA3130513A patent/CA3130513A1/en active Pending
- 2020-03-18 AU AU2020240035A patent/AU2020240035A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021018545A2 (pt) | 2021-12-14 |
| CN113905763A (zh) | 2022-01-07 |
| EP3942061A1 (en) | 2022-01-26 |
| CA3130513A1 (en) | 2020-09-24 |
| JP2022525476A (ja) | 2022-05-16 |
| EP3942061A4 (en) | 2022-12-14 |
| WO2020190990A1 (en) | 2020-09-24 |
| AU2020240035A1 (en) | 2021-10-07 |
| US20220160703A1 (en) | 2022-05-26 |
| KR20220004025A (ko) | 2022-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013974A (es) | Metodos, sistemas y dispositivos de seleccion de pacientes tl1a. | |
| CO2021006075A2 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| MX2022012992A (es) | Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas. | |
| MX2021013225A (es) | Composiciones y metodos para el tratamiento del cancer utilizando una terapia de celulas t modificadas de cd8. | |
| CL2021002533A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras | |
| CO2017011197A2 (es) | Terapia de combinación fgfr/pd-1 para el tratamiento del cancer | |
| UY38160A (es) | Partículas implantables y métodos relacionados | |
| ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
| AR118859A1 (es) | Composiciones y métodos de fabricación de células t | |
| GT201700246A (es) | Métodos y kits para tratar la depresión | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| MX388914B (es) | Un inhibidor de punto de control y una celula de mycobacterium para su utilizacion en el tratamiento contra cancer. | |
| CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
| MX2016015346A (es) | Metodos de tratamiento de cancer con antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| PE20211961A1 (es) | Terapia de combinacion de radioinmunoconjugados con inhibidores de danos y reparaciones del adn | |
| ES2422605T3 (es) | Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares | |
| NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| CO2023001561A2 (es) | Combinaciones para el tratamiento de cáncer | |
| ECSP11010824A (es) | Tratamiento para diabetes en pacientes inapropiados para terapia con metformina. | |
| MX2021000828A (es) | Uso de farmacos bioactivables por nqo1 para mejorar la actividad inhibidora de parp1. | |
| CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
| UY35439A (es) | Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (S)-quinuclidin-3-ilo. | |
| BR112023020669A2 (pt) | Terapias de combinação para o tratamento de câncer | |
| MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. | |
| BR112019005815A2 (pt) | métodos de tratamento de um indivíduo com câncer de mama, kit para o tratamento de câncer de mama e combinação de fármacos para terapia de câncer de mama |